PUT/NOVO-NORDISK B/1500/0.1/20.09.24 | Real-time BOERSE MUENCHEN 19:25:49 11/06/2024 BST | ||
| 6.97 EUR | +0.72% |
|
| Current month | -9.90% | ||
| 1 month | -16.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 6.97 | +0.72% |
| 10/06/24 | 6.92 | -0.43% |
| 07/06/24 | 6.95 | -2.66% |
| 06/06/24 | 7.14 | -5.56% |
| 05/06/24 | 7.56 | -0.79% |
Real-time BOERSE MUENCHEN
Last update June 11, 2024 at 07:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4V3W |
| ISIN | DE000GQ4V3W6 |
| Date issued | 13/09/2023 |
| Strike | 1,500 kr |
| Maturity | 20/09/2024 (101 Days) |
| Parity | 10 : 1 |
| Emission price | 10.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.8 € |
|---|---|
| Lowest since issue | 6.82 € |
| Spread | 0.07 € |
| Spread % | 1.00% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
